4Sc (VSC.DE) Stock Price
4Sc Price
Revenue at 4Sc has contracted by 4.4% per year over the past 19 years to 436,000.00 EUR. For 4Sc, the net margin of -3,293.8% is down versus -423.2% a few years ago. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.
4Sc stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of 4Sc over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how 4Sc stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing 4Sc's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | 4Sc Price |
|---|
4Sc Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
4Sc Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| SHARESM |
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | 4.00 | 4.00 | 7.00 | 3.00 | 2.00 | 4.00 | 4.00 | 2.00 | 2.00 | 14.00 | – | 12.00 | 31.00 | 77.00 |
| – | – | – | – | 75.00 | -57.14 | -33.33 | 100.00 | – | -50.00 | – | 600.00 | – | – | 158.33 | 148.39 |
| – | – | 100.00 | 75.00 | 28.57 | 33.33 | 50.00 | 75.00 | 75.00 | 50.00 | 50.00 | 92.86 | – | 92.86 | 92.86 | 92.86 |
| 13.00 | 13.00 | 4.00 | 3.00 | 2.00 | 1.00 | 1.00 | 3.00 | 3.00 | 1.00 | 1.00 | 13.00 | 13.00 | 11.14 | 28.79 | 71.50 |
| -20.00 | -18.00 | -13.00 | -10.00 | -9.00 | -9.00 | -12.00 | -10.00 | -17.00 | -14.00 | -19.00 | -8.00 | -13.00 | -2.00 | -3.00 | -5.00 |
| – | – | -325.00 | -250.00 | -128.57 | -300.00 | -600.00 | -250.00 | -425.00 | -700.00 | -950.00 | -57.14 | – | -16.67 | -9.68 | -6.49 |
| -20.00 | -19.00 | -13.00 | -10.00 | -9.00 | -9.00 | -11.00 | -10.00 | -17.00 | -13.00 | -18.00 | -10.00 | -14.00 | -2.00 | -4.00 | -7.00 |
| 25.00 | -5.00 | -31.58 | -23.08 | -10.00 | – | 22.22 | -9.09 | 70.00 | -23.53 | 38.46 | -44.44 | 40.00 | -85.71 | 100.00 | 75.00 |
| 45.97 | 45.97 | 45.97 | 45.97 | 45.97 | 45.97 | 4.18 | 4.18 | 6.75 | 6.37 | 10.11 | 10.11 | 10.11 | 10.11 | 10.11 | 10.11 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales 4Sc generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue 4Sc retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare 4Sc's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares 4Sc has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against 4Sc's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
4Sc stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
4Sc Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
4Sc business model & stock analysis
4Sc SWOT Analysis
Strengths
4Sc AG possesses several strengths that contribute to its success. The company has a strong portfolio of innovative products in the field of cancer immunotherapy and autoimmune diseases. These products have shown promising results in clinical trials, which positions 4Sc AG as a leader in this therapeutic area. Additionally, the company has a team of highly skilled and experienced researchers and scientists who drive the development and advancement of their product pipeline. This expertise and knowledge enable 4Sc AG to stay ahead of competitors and maintain a competitive edge in the market.
Weaknesses
Despite its strengths, 4Sc AG also faces certain weaknesses. One notable weakness is the company's heavy dependency on the success of its product pipeline. Any failure or delay in the development or approval of these products could significantly impact 4Sc AG's financial performance. Moreover, the company operates in a highly competitive and regulated industry, which poses challenges in terms of pricing pressures, stringent regulatory requirements, and the need for continuous innovation. Addressing these weaknesses is crucial for sustaining growth and profitability.
Opportunities
4Sc AG operates in a market with significant growth opportunities. The rise in the prevalence of cancer and autoimmune diseases, coupled with the increasing demand for more effective and targeted therapies, presents a favorable market environment for 4Sc AG's product portfolio. Furthermore, advancements in technology, such as personalized medicine and gene therapies, provide opportunities for strategic partnerships and collaborations, enabling the company to expand its reach and accelerate product development. By capitalizing on these opportunities, 4Sc AG can enhance its market position and revenue potential.
Threats
While there are opportunities, 4Sc AG also faces potential threats to its business. One significant threat is the intense competition in the market from both established pharmaceutical companies and emerging biotech firms. This competition poses challenges in terms of market share, pricing, and differentiation of products. Additionally, the regulatory landscape in the healthcare industry adds uncertainty and potential hurdles to the development, approval, and commercialization of 4Sc AG's products. Other threats include changes in healthcare policies, intellectual property disputes, and the possibility of unforeseen adverse events during clinical trials. These threats necessitate a proactive approach to risk management and strategic decision-making for 4Sc AG to navigate potential challenges effectively.
4Sc Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
4Sc historical P/E ratio, EBIT multiple, and P/S ratio
4Sc annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
4Sc shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
4Sc stock splits
Current 4Sc forecasts and price targets in August 2026
Analyst Price Targets 20264Sc Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/9/2011 | -3.22EUR | - | -EUR | - | 2011 Q2 |
4Sc shareholder structure
| % | Name |
|---|---|
70.30006% |
Frequently asked questions about 4Sc
4Sc AG, a renowned biotech company, operates on an innovative business model focusing on the research and development of targeted small molecule drugs. The company specializes in the discovery and advancement of novel therapies in the field of immune-oncology and autoimmune diseases. By leveraging its proprietary technology platforms, 4Sc AG aims to identify promising drug candidates and advance them through pre-clinical and clinical development phases. With a strong emphasis on precision medicine, 4Sc AG endeavors to develop tailored treatments that address the specific needs of patients. By combining cutting-edge science with a patient-centric approach, 4Sc AG is dedicated to revolutionizing the treatment landscape in various diseases and making a positive impact on patients' lives.
4Sc AG is primarily active in the biotechnology industry.
The main competitors of 4Sc AG in the market include pharmaceutical companies such as Roche Holding AG, Novartis AG, and Bristol-Myers Squibb Company.
4Sc AG is a German biopharmaceutical company focused on the development of innovative immunotherapies for cancer treatment. Established in 2007, 4Sc AG has rapidly grown and positioned itself as a pioneer in the field of personalized medicine. The company concentrates on developing targeted therapies that activate the patient's immune system to fight tumors effectively. With a strong emphasis on research and development, 4Sc AG has built a diverse pipeline of drug candidates aiming to address several cancer indications. The company's commitment to scientific excellence and patient-centric approach has garnered recognition within the medical and investment communities. 4Sc AG continues to strive towards providing groundbreaking solutions in the fight against cancer.
Some of the significant milestones achieved by 4Sc AG include the successful initiation of Phase II clinical trials for their lead product, resminostat, in several indications such as hepatocellular carcinoma and cutaneous T-cell lymphoma. The company has also formed strategic partnerships and collaborations to advance their pipeline, including a collaboration with immunotherapy-focused biotech, BioNTech. Additionally, 4Sc AG has received multiple grants and funding awards to support their research and development efforts. These achievements highlight 4Sc AG's commitment to advancing innovative therapies and their potential to deliver breakthrough treatments in the field of oncology.
4Sc AG is primarily present in Germany and Europe.
4Sc AG is a leading biopharmaceutical company that is committed to pioneering innovative therapies for patients with severe diseases. The company's corporate philosophy revolves around the core values of dedication, collaboration, and excellence. By maintaining a patient-centric approach, 4Sc AG aims to develop breakthrough treatments with the potential to improve the lives of individuals worldwide. With a focus on scientific expertise and ethical practices, 4Sc AG consistently strives to optimize its research and development efforts, ultimately aiming to provide effective and safe therapies that address unmet medical needs.
5 analysts currently rate the 4Sc stock: 4 recommend buying, 1 holding and 0 selling.
The 4Sc share (VSC.DE) is listed on 1 stock exchanges, including: XETRA (VSC.DE).
The 4Sc AG is a biopharmaceutical company specializing in the development of drugs for the treatment of cancer. The company is divided into two divisions: 4SC Discovery and 4SC Clinical Development. 4SC Discovery focuses on the research and development of new drugs, while 4SC Clinical Development is responsible for conducting clinical trials and obtaining market approval for the drugs. The company utilizes innovative technologies and methods, with a focus on epigenetics, to develop new drug candidates. Resminostat is a promising drug candidate being developed for the treatment of solid tumors and hematological malignancies. 4SC works closely with external partners, including academic institutions and pharmaceutical companies, to bring their drug candidates to market. The overall business model is focused on developing innovative drugs for cancer patients and expediting the development process through research, partnerships, and collaboration.
The revenue cannot currently be calculated for 4Sc.
The profit cannot currently be calculated for 4Sc.
The P/E ratio cannot be calculated for 4Sc at the moment.
The P/S cannot be calculated for 4Sc currently.
The Eulerpool Quality Score for 4Sc is 2/10.
The ISIN of 4Sc is DE000A14KL72. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of 4Sc is A14KL7. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of 4Sc is VSC.DE. The ticker symbol is used to trade 4Sc shares on the stock exchange.
4Sc is assigned to the 'Health' sector.
The dividends of 4Sc are distributed in EUR.
4Sc stock
4Sc Ticker
4Sc FIGI
All fundamentals and in-depth analysis of 4Sc
Our stock analysis for 4Sc stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of 4Sc. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.